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Clinical Integration

Overview

exploring a possible correlation between CA
15-3, a serum marker already used in treating
patients with metastatic breast and ovarian
cancer, and high expression of MUC-1.
“No one had looked at using CA 15-3 in
patients with pancreatic cancer, probably
because this marker won’t be elevated in
all pancreatic cancer patients,” Dr. Winter
explains. “However, if we find a reliable
correlation between CA 15-3 and MUC-1,
testing CA 15-3 levels may have a role in
pancreatic cancer treatment.”

Charles J. Yeo, MD, FACS
Samuel D. Gross Professor and
Chair, Department of Surgery

In this issue, Surgical Solutions focuses
on our trauma expertise, recent progress
in bench research, the contributions of
Dr. Gerald Isenberg, insights from medical
student Zhi Ven Fong, and pays tribute to
Dr. John Moore. A very busy issue!
I was moved by a recent editorial in the New
England Journal of Medicine dated February
16, 2012. In the piece entitled “What We
Talk About When We Talk About Health Care
Costs”, Peter Neumann of Tufts University
quotes from the American College of
Physicians Ethics Manual, 6th edition:
“Physicians have a responsibility to
practice effective and efficient health
care and to use health care resources
responsibly. Parsimonious care that utilizes
the most efficient means to effectively
diagnose a condition and treat a patient
respects the need to use resources wisely
and to help insure that resources are
equitably available.”
Webster’s dictionary defines parsimony
as “carefulness in the expenditure of
money or resources”. Synonyms are
frugal, stingy or penurious.
Neumann’s editorial is an important read
for all in health care delivery. The debate
about health care costs will continue. We
recognize that non-adherence to clinical
pathways, variations in how we treat
patients, re-admissions, and preventable
errors all drive up health care costs.
In the big picture though, Neumann nails
the issue… “The problem is that no one in
charge seems willing to acknowledge that
getting a handle on cost growth will also
involve uncomfortable trade-offs. We cannot
as a society provide patients with unlimited
access and unlimited choice. Providing
better-quality care, though it is vital, won’t
change that reality.”
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Drs. Jordan Winter and Hwyda Arafat are key players in the world class pancreatic cancer
research team that has been assembled at Jefferson over the last six years.

Jefferson Researchers Identify Potential Diagnostic,
Prognostic Tools for Pancreatic Cancer
When it comes to diagnosing and treating
cancer, early detection is important. While
other cancers can be identified through
routine screenings, pancreatic cancer has been
notoriously difficult to diagnose early. After
pancreatic cancer is diagnosed, the optimal
course of treatment is not always clear.
Hwyda Arafat, MD, PhD, Associate Professor
of Surgery at Thomas Jefferson University and
co-director of the Jefferson Pancreatic, Biliary
and Related Cancers Center, and Jordan M.
Winter, MD, Assistant Professor of Surgery,
are working to change that.
Together with Mon-Li Chu, PhD, Professor
and Vice Chair of the Department of
Dermatology and Cutaneous Biology, Dr.
Arafat has identified a protein – Collagen
6A3 – that is highly expressed in cancerous
pancreatic tissue and can be identified through
a noninvasive blood test.
Based on their initial findings, Dr. Arafat and
Dr. Chu were awarded a $200,000 grant from
the University City Science Center’s QED
Proof of Concept Program. The team is using
the money to validate their initial findings
and to begin commercializing the test – “The
COL6A3 Panel” – which is poised to become
the first clinically reliable test for pancreatic
ductal adenocarcinoma.
“We are exploring how this test could be used
to monitor high-risk patient groups, such as
those with chronic pancreatitis and those with a
family history of pancreatic cancer,” Dr. Arafat
explains. “This noninvasive test could also
help in differentiating between malignant and
benign tumors identified in imaging studies,
and could be used to monitor pancreatic cancer
patients as they undergo treatment.”

As Dr. Arafat works to develop a screening
test, Dr. Winter is working to identify more
effective prognostic tools. His work has
explored the linkage between two proteins,
MUC-1 and mesothelin, and pancreatic
tumors with particularly aggressive biology.
More specifically, Dr. Winter and his team are

What’s more, Dr. Winter is collaborating with
Jonathan R. Brody, PhD, J. Wallace Davis and
Gail G. Davis Professor of Surgery, to research
gene therapies targeting pancreatic cancer
at a molecular level: “What we imagine is a
clinical paradigm where we can identify which
patients are most appropriate for gene therapy
based on the results of their serum test,” Dr.
Winter says.
Watch Drs. Arafat and Winter discuss
their research projects at last year’s patient
symposium: www.jeffersonhospital.org/
pancreasevent

Faculty Profile
Gerald A. Isenberg, MD, FACS
As Professor of Surgery, Division of
Colorectal Surgery; Director, Surgical
Undergraduate Education, Jefferson Medical
College (JMC); Program Director, Colorectal
Residency Program, Thomas Jefferson
University Hospital; and Chair, Curriculum
Committee, JMC, Gerald A. Isenberg,
MD, FACS, is equally focused on – and
passionate about – clinical practice and
medical education.
Indeed, as he reflects on his career at
Jefferson, which spans nearly 25 years, Dr.
Isenberg is appreciative of the opportunity to
build a busy and vibrant colorectal surgery
practice. But he clearly also values his
experiences as an educator – particularly
the many opportunities to lead and innovate.
In years past, Dr. Isenberg spearheaded
the adoption of Problem-Based Learning,
a teaching method designed to strengthen
students’ critical-thinking skills. He also
chaired a taskforce that explored the topic of
professionalism and developed a blueprint
for infusing professionalism throughout the
curriculum.
About 10 years ago, Dr. Isenberg created a
fourth-year course, “Scientific Foundations
of Clinical Medicine,” in which students

revisit some of the basic sciences they learned
early in medical school and explore how they
apply to clinical medicine. These days, Dr.
Isenberg is part of a team that’s exploring
health information technology and its impact on
medical education and the practice of medicine.
“As a teacher, I continue to emphasize the
importance of critical thinking,” Dr. Isenberg
says. “The information explosion in medicine
makes it impossible to assimilate all medical
knowledge. Instead, I focus on planting seeds –
teaching students how to nurture and fine-tune
their reasoning skills.”
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